Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Pilot Trial Evaluating the Safety and Pharmacodynamic Effects of SRD-001 (AAV1-SERCA2a) in Subjects With Heart Failure With Preserved Ejection Fraction

Next Previous
Trial Profile

A Phase 1b, Pilot Trial Evaluating the Safety and Pharmacodynamic Effects of SRD-001 (AAV1-SERCA2a) in Subjects With Heart Failure With Preserved Ejection Fraction

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SERCA 2a gene therapy (Primary)
  • Indications Diastolic heart failure; Heart failure
  • Focus First in man; Therapeutic Use
  • Acronyms MUSIC-HFpEF
  • Sponsors Sardocor

Most Recent Events

  • 13 Jun 2025 According to a Medera media release, data from this trial was presented at the 2025 International Society for Stem Cell Research (ISSCR) Annual Meeting, held June 11 to 14 in Hong Kong.
  • 19 May 2025 According to a MedERA media release, company presented positive interim result data from this study at the Heart Failure 2025 Congress taking place in Belgrade, Serbia.
  • 12 May 2025 According to a MedERA media release, company announced that data from this study will be presented at the upcoming Heart Failure 2025 Congress taking place at Duke University Medical Center, on May 18, 2025, at 14:05 CEST during the "Late-Breaking Clinical Trials in Chronic Heart Failure" session.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top